Oligonucleotide Therapeutics
•45 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (45)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Oligonucleotide therapeutics focus includes antisense/siRNA approaches.
|
$816.66B |
$863.11
+2.20%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
VX-670 is an oligonucleotide therapy, fitting the oligonucleotide therapeutics category.
|
$109.29B |
$425.63
+1.37%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
C5 programs use oligonucleotide chemistry (siRNA) and relate to oligonucleotide therapeutics.
|
$69.08B |
$651.52
-0.39%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
ALNY's platform centers on oligonucleotide therapeutics (siRNA) for gene silencing, a major oligonucleotide therapeutics category.
|
$59.78B |
$456.03
+1.44%
|
|
BIIB
Biogen Inc.
Biogen develops antisense oligonucleotide therapies (e.g., QALSODY, BIIB080), i.e., oligonucleotide therapeutics.
|
$22.62B |
$154.27
+3.11%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$11.84B |
$74.28
+0.15%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$8.42B |
$69.83
+0.20%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
ARWR develops oligonucleotide-based therapeutics (siRNA) across tissues, fitting Oligonucleotide Therapeutics.
|
$5.85B |
$42.40
+0.20%
|
|
CRSP
CRISPR Therapeutics AG
SRSD107 is an oligonucleotide-based therapeutic (siRNA), fitting Oligonucleotide Therapeutics.
|
$5.53B |
$64.02
+4.78%
|
|
PRAX
Praxis Precision Medicines, Inc.
Solidus platform develops antisense oligonucleotide (ASO) therapeutics (e.g., elsunersen).
|
$4.05B |
$198.91
-1.04%
|
|
QURE
uniQure N.V.
Oligonucleotide-based therapeutics (antisense/siRNA) as a modality applicable to the company’s gene-silencing approach.
|
$3.71B |
$67.67
-0.28%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
GTX-102 is an antisense oligonucleotide with LNA chemistry, placing Ultragenyx in Oligonucleotide Therapeutics.
|
$3.27B |
$34.58
-1.68%
|
|
DYN
Dyne Therapeutics, Inc.
Payloads include oligonucleotide-based therapies (e.g., antisense/siRNA) delivered via FORCE, classifying Dyne as an Oligonucleotide Therapeutics company.
|
$2.57B |
$22.59
-4.08%
|
|
SRPT
Sarepta Therapeutics, Inc.
Exon-skipping PMOs are oligonucleotide therapeutics, a major Sarepta modality.
|
$2.36B |
$24.00
+3.23%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$1.64B |
$30.01
-5.33%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$1.39B |
$9.04
+8.86%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0114 is an antisense oligonucleotide, fitting the 'Oligonucleotide Therapeutics' investable theme.
|
$1.24B |
$13.93
-0.85%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is a GalNAc-conjugated oligonucleotide therapeutic, placing the company in the oligonucleotide therapeutics space.
|
$905.92M |
$4.72
-2.48%
|
|
VIR
Vir Biotechnology, Inc.
SiRNA-based therapeutics align with Oligonucleotide Therapeutics as a major modality.
|
$823.90M |
$5.95
+0.34%
|
|
GERN
Geron Corporation
Imetelstat is an oligonucleotide therapeutic, a major category of biotech cancer drugs.
|
$802.52M |
$1.26
+1.61%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$799.63M |
$3.13
-0.16%
|
|
FDMT
4D Molecular Therapeutics, Inc.
Inhibitory miRNA and oligonucleotide components described in 4D-150 suggest an oligonucleotide therapeutics approach.
|
$532.73M |
$11.52
+1.77%
|
|
BNTC
Benitec Biopharma Inc.
ddRNAi-based therapies are oligonucleotide payloads, classifying under Oligonucleotide Therapeutics.
|
$418.82M |
$16.37
+1.24%
|
|
KRRO
Korro Bio, Inc.
KRRO's core offering is its OPERA oligonucleotide platform enabling RNA editing therapeutics (oligonucleotide-based editing).
|
$384.17M |
$41.05
+12.61%
|
|
SLN
Silence Therapeutics plc
Company develops siRNA oligonucleotide therapeutics, aligning with the oligonucleotide therapeutics theme.
|
$337.72M |
$7.10
-2.87%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
mRNA is a nucleic acid therapeutic, aligning with the oligonucleotide therapeutics category.
|
$270.39M |
$9.98
+3.69%
|
|
TRDA
Entrada Therapeutics, Inc.
Lead and pipeline oligonucleotide programs (e.g., exon-skipping approaches) align with Oligonucleotide Therapeutics as a direct product area.
|
$263.78M |
$6.96
+0.87%
|
|
VYGR
Voyager Therapeutics, Inc.
siRNA payloads align with Oligonucleotide Therapeutics (oligonucleotide-based therapies).
|
$258.42M |
$4.67
+3.32%
|
|
VNDA
Vanda Pharmaceuticals Inc.
antisense oligonucleotide–based therapeutics (ASOs) like VCA-894A align with Oligonucleotide Therapeutics.
|
$257.04M |
$4.33
+0.35%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$231.68M |
$2.75
+0.92%
|
|
CDXS
Codexis, Inc.
The ECO Synthesis platform enables oligonucleotide manufacturing (siRNA), aligning with oligonucleotide therapeutics production.
|
$196.34M |
$2.36
|
|
THTX
Theratechnologies Inc.
Ionis partnership includes donidalorsen and olezarsen, both oligonucleotide therapeutics.
|
$155.87M |
$3.39
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$152.48M |
$4.67
+2.98%
|
|
ALEC
Alector, Inc.
SiRNA-based therapies fall under oligonucleotide therapeutics (siRNA is an oligonucleotide).
|
$146.99M |
$1.48
-2.96%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$83.87M |
$4.13
+2.61%
|
|
ALGS
Aligos Therapeutics, Inc.
The company references an antisense oligonucleotide (ASO) platform for HBV, aligning with oligonucleotide therapeutics.
|
$50.45M |
$8.34
+1.65%
|
|
OTLC
Oncotelic Therapeutics, Inc.
OT-101 is an antisense oligonucleotide targeting TGFB2, fitting the Oligonucleotide Therapeutics category.
|
$38.62M |
$0.10
|
|
GBIO
Generation Bio Co.
SiRNA therapeutics are oligonucleotide-based therapies.
|
$36.94M |
$5.41
-1.64%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-KIT uses oligonucleotide-based mechanisms (antisense), fitting oligonucleotide therapeutics.
|
$18.76M |
$1.41
+3.68%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL utilizes oligonucleotide chemistry (siRNA) as the active modality.
|
$9.84M |
$2.04
-1.21%
|
|
RNAZ
TransCode Therapeutics, Inc.
Therapeutics based on oligonucleotides (antisense/siRNA/miRNA inhibitors) are a core focus.
|
$9.34M |
$11.18
+2.10%
|
|
SBFM
Sunshine Biopharma, Inc.
K1.1 mRNA therapy constitutes an oligonucleotide-based therapeutic approach (mRNA).
|
$8.06M |
$1.78
+2.00%
|
|
IMNN
Imunon, Inc.
DNA plasmid-based therapeutics align with Oligonucleotide Therapeutics.
|
$4.43M |
$4.54
+1.22%
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is a dsRNA-based oligonucleotide therapeutic, aligning with the oligonucleotide therapeutics category.
|
$1.60M |
$2.10
|
|
RGBP
Regen BioPharma, Inc.
DiffronC utilizes oligonucleotide-based approaches (siRNA), aligning with Oligonucleotide Therapeutics.
|
$409265 |
$0.01
|
Loading company comparison...
Loading industry trends...
Loading research report...
